ABSTRACT -HTLV-I has been associated with a chronic idiopatic spastic paraparesis (CHISPA) in man; however, a complete understanding of this association is still debated. We selected the most comprehensible papers on this topic between 1985 and 1996, and found that 1261 out of 2811 patients (44.9%) reported, throughout the world, were HTLV-I positive. The mean age was 39.5 years and there was a female predominance of 1.9:1. These results do not exclude the causality of HTLV-I as a germen associated to CHISPA; however, other causes (e.g., toxic, immunosuppressors) must be considered as participating in the multistep neurodegeneration observed in CHISPA throughout the world.
The history of these CHISPA changed drastically after Poiez et al. 41 discovered, in the earliest 80's, a retrovirus type C called human T lymphotropic virus type I (HTLV-I). Soon thereafter, an association was found between this retrovirus and some types of CHISPA almost simultaneously in both tropical and temperate countries such as Martinique, Jamaica, Colombia and Japan''-39 - 43 - 63 . Subsequently, HTLV-I-associated myelopathy (HAM), as described in Japan by Osame et al. 39 , and TSP were considered the same clinical entity 44 .
However, despite more than 10 years of intensive research on retrovirus-associated-CHISPA, there is still not a consensus on the etiology of this entity. It is of interest to note that several places with high rates of HTLV-I seropositivity show few, if any, patients with CHISPA; likewise, only 1 out of 1000 infected people with HTLV-I virus develop the clinically manifest disease 52 , and clinically similar cases, which are totally seronegative against any retroviral infection, have been found in almost all of those areas where HTLV-I is considered endemic. All of these situations have been puzzling and remain as unsolved questions 62 .
In order to get a better knowledge on the epidemiology of this disease and try to obtain more clues to help us in understanding the pathogenesis of this, and probably other diseases associated with this retrovirus, we decided to do a meta-analysis on the main worldwide publications on CHISPA -HAM/TSP-between 1985 and 1996, including our experience. A close review related to this topic was recently presented in a book 62 ; however, as far as we know, the data gathered here have not been presented in a peer-review journal yet. We consider that the results found here must be taken into account in further neuroepidemiological studies if we want actually to clarify the pathogenesis of these hidden endemies 45 -62 -65 .
METHODS
The methodology followed in this study was very similar to that recently described by De Castro Costa et al. 8 . We collected and analyzed the papers published on HAM/TSP in international journals from all countries but India, Peru and Japan 4 *-53 -3 '- 62 . For these latter countries the included data were taken from books recently published on this matter. In all countries but India and Zaire the clearest study was chosen for this study 1 -9 -23 ' 46 . In these two countries two and three papers respectively were included because controversial results have been reported previously. Since papers with at least five patients affected by retroviral infections have impacted the epidemiology of these diseases 38 -39 we decided to take into account manuscripts reporting five or more patients with CHISPA. In all but two countries (Thailand, Bangladesh) confirmatory serological tests were commonly performed including the polymerase chain reaction (PCR) method. Because an interesting study analyzing several case-control studies on CHISPA was alredy done we did not think it necessary to perform a similar investigation here 34 . It could happen that some papers were, by chance, ommitted; if so, we apologize to their authors for such mistake as thaught elsewhere 9 . Table, there are many cases of CHISPA throughout the world which still remain negative for HTLV-I. It was interesting to note that almost all of those patients from class I area (80% or more of retroviral seropositivity) were black or African natives, belonged to the lower socioeconomic classes, usually lived in rural areas as well as in islands with hot and humid regions such as Seychelles, Zaire, Jamaica, Dominican Republic, Trinidad and Tobago, Southwestern Colombia and Northwest Ecuador, or were inmigrants from the West Indies to United Kingdom. The class II/III areas(40% to 80% of retroviral seropositivity) were found in both tropica 1 
RESULTS
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DISCUSSION
Even though there is a lack of demographic information from some places with CHISPA, it is possible to observe that the data gathered here are quite dissimilar with respect to the presence of retrovirus infection. It was also interesting to observe that there was a predominance of mate and mestizo patients in seronegatives CHISPA from Colombia 62,65 , unfortunately the lack of data already commented above in both HTLV-I seropositive and seronegative CHISPA prevent us from doing a wider demographic comparison worthy of publication.
Although we agree with the suggestion of using a worldwide common clinical and epidemiological protocol to overcome many gaps found in the different studies performed throughout the world on CHISPA 9 , the discrepancies observed in this study do not seem to be due mainly to case definition; nor do we consider that such differences could be due to lack of test sensitivity because the results were re-confirmed by different serological tests including, in several cases, the PCR method, including a still controversial country such as India 7 In either case, the uneven distribution observed by us in this study between HTLV-I and CHISPA throughout the world does not preclude the association of HTLV-I with the diseases commented above or, probably with another 20 or more diseases described elsewhere 62 ; however, correlation or association does not mean causation. The discrepancy found in these data strongly suggests that the so-called cofactors (named by us distracters) other than HTLV-I infection seem to play an importam and definitive role in disease manifestation and evolution 29 
